More articles from Idiopathic interstitial pneumonias

Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients
Alan Montgomery, Kelly Otto, Jun Khoo, Ian Glaspole

European Respiratory Journal Sep 2018, 52 (suppl 62) OA266; DOI: 10.1183/13993003.congress-2018.OA266
INTERSTITIAL LUNG DISEASE IN A LUNG CANCER SCREENING PROGRAM: PREVALENCE AND ASSOCIATION WITH CANCER.
Aranzazu Campo Ezquibela, Amaia Merino Hernandez, Jessica Gonzalez Gutierrez, Marta Marin Oto, Ana Belen Alcaide Ocana, Juan Pablo De Torres Tajes, Javier Zulueta Frances

European Respiratory Journal Sep 2018, 52 (suppl 62) OA544; DOI: 10.1183/13993003.congress-2018.OA544
Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes
Nahal Mansouri, Gareth R. Willis, Angeles Fernandez-Gonzalez, Monica Reis, S. Alex Mitsialis, Stella Kourembanas

European Respiratory Journal Sep 2018, 52 (suppl 62) OA261; DOI: 10.1183/13993003.congress-2018.OA261
Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study
Peter Wung, Ganesh Raghu, Bruno Crestani, Luca Richeldi, Corinne Esperet, Christina Soubrane

European Respiratory Journal Sep 2018, 52 (suppl 62) OA540; DOI: 10.1183/13993003.congress-2018.OA540
Late Breaking Abstract - A Deep Learning Algorithm for Classifying Fibrotic Lung Disease on High Resolution Computed Tomography
Simon Walsh, Lucio Calandriello, Mario Silva, Nicola Sverzellati

European Respiratory Journal Sep 2018, 52 (suppl 62) OA262; DOI: 10.1183/13993003.congress-2018.OA262
A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey
Michael Kreuter, Markus Polke, Simon Walsh, Harold R Collard, Nazia Chaudhuri, Sergey Avdeev, Juergen Behr, Greg Calligero, Tamera Corte, Kevin Flaherty, Manuela Funke, Martin Kolb, Yasuhiro Kondoh, Toby M. Maher, Maria Molina Molina, Antonio Morais, Karen Moor, Julie Morisset, Carlos Pereira, Silvia Quadrelli, Moises Selman, Argyrios Tzouvelekis, Carlo Vancheri, Vanesa Vicens-Zygmunt, Julia Waelscher, Wim Wuyts, Marlies Wijsenbeek, Vincent Cottin, Elisabeth Bendstrup

European Respiratory Journal Sep 2018, 52 (suppl 62) OA542; DOI: 10.1183/13993003.congress-2018.OA542
Late Breaking Abstract - Prognostic analysis of secondary pulmonary alveolar proteinosis: Inspection by one of the world’s largest data.
Haruyuki Ishii, Ryushi Tazawa, Takeshi Saraya, Yoshikazu Inoue, Koh Nakata

European Respiratory Journal Sep 2018, 52 (suppl 62) OA265; DOI: 10.1183/13993003.congress-2018.OA265
Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial
Martin Kolb, Athol Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Ganesh Raghu, Fernando J Martinez

European Respiratory Journal Sep 2018, 52 (suppl 62) OA546; DOI: 10.1183/13993003.congress-2018.OA546
Late Breaking Abstract - Idiopathic Pulmonary Fibrosis – a worldwide review of ‘real’ life’ practice: experience from a treatment feasibility review in 41 countries
Marlies S. Wijsenbeek, Florin Floricel, Joelle Thonnard, Ann Fieuw, Paul Ford, Eva Santermans, Charlotte Vandenrijn, Toby Maher

European Respiratory Journal Sep 2018, 52 (suppl 62) OA263; DOI: 10.1183/13993003.congress-2018.OA263

Main menu

User menu

Search

More articles from Idiopathic interstitial pneumonias

Pages

Contact us